Marinomed Biotech AG Logo

Marinomed Biotech AG

Develops treatments for viral infectious diseases and immunological disorders.

MARI | VI

Overview

Corporate Details

ISIN(s):
ATMARINOMED6
LEI:
529900GN3B1EN80XF405
Country:
Austria
Address:
Hovengasse 25, 2100 Korneuburg

Description

Marinomed Biotech AG is a biopharmaceutical company that develops medicinal products and medical devices for viral infectious diseases and immunological disorders. The company's innovation is driven by proprietary, patent-protected technology platforms. The Marinosolv platform enhances the solubility and bioavailability of poorly soluble compounds, enabling the development of treatments for immunological conditions such as allergies, asthma, and inflammatory diseases. The virology platform is the basis for therapies targeting viral respiratory infections. Marinomed maintains a development pipeline, has globally marketed therapeutics, and offers its technology through partnerships and services via its Solv4U unit.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 10:01
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 Börs…
English 16.5 KB
2025-10-31 10:01
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 13…
German 17.0 KB
2025-10-31 10:00
Release according to Article 135, Section 1 BorseG with the objective of Europe…
English 3.6 KB
2025-10-06 14:58
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Mari…
English 34.6 KB
2025-10-06 14:58
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die …
German 36.4 KB
2025-10-06 14:56
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv plat…
English 11.1 KB
2025-09-17 13:48
Marinomed Biotech AG announces results for the first half year of 2025
English 10.6 KB
2025-09-17 13:42
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
English 3.4 MB
2025-09-17 13:42
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines F…
German 3.5 MB
2025-09-16 15:24
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory s…
English 31.7 KB
2025-09-16 15:24
EQS-Adhoc: Marinomed Biotech AG beschließt Kapitalerhöhung unter Bezugsrechtsau…
German 33.7 KB
2025-09-16 15:22
Marinomed Biotech AG resolves capital increase excluding statutory subscription…
English 8.0 KB
2025-09-02 09:18
EQS-AGM: Marinomed Biotech AG: Convening of an Extraordinary General Meeting fo…
English 51.6 KB
2025-09-02 09:17
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversamml…
German 50.1 KB
2025-09-02 09:16
Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday…
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all Marinomed Biotech AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marinomed Biotech AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Marinomed Biotech AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.